BCL2 and cancer: Downregulation of pro‐apoptotic elements (e.g. MDM2), and upregulation of anti‐apoptotic proteins (e.g., BCL2) may confer a survival advantage to cancer cells67 in response to DTX (Figures S2 and S3).